Safety Data on Deucravacitinib

EP: 1.Overview of the Recent Development in the Treatment Landscape: Plaque Psoriasis

EP: 2.The Evolving Role of Advanced Practice Providers Treating Plaque Psoriasis

EP: 3.Plaque Psoriasis as a Systemic Disease

EP: 4.The Oral Systemic Space of Plaque Psoriasis

EP: 5.Lab Requirements and Monitoring of Deucravacitinib Treatment

EP: 6.Recent Long Term Clinical Trial Data on Deucravacitinib

Now Viewing

EP: 7.Safety Data on Deucravacitinib

EP: 8.Impact of the Expanding Treatment Landscape on the Treatment Algorithm of Plaque Psoriasis

EP: 9.Good Candidates for TYK2 Inhibitors

EP: 10.Patient Experience With Oral Systemic Treatments

EP: 11.Selecting Appropriate Therapy in the Evolving Treatment Landscape of Plaque Psoriasis

Summary

In this series, dermatologists TJ Chao and Kristine Kucera delve into recent developments in plaque psoriasis treatment, including the emergence of TYK2 inhibitors. They highlight the evolving role of physician assistants in managing plaque psoriasis and discuss its recognition as a systemic disease. The conversation covers lab and monitoring requirements for TYK2 inhibitors like deucravacitinib, alongside a review of short- and long-term clinical trial data. Chao and Kucera offer insights into patient selection and the patient experience with oral systemic agents, providing guidance for selecting appropriate therapies in the expanding treatment landscape.

This summary was AI-generated and edited for clarity.